[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599804":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":41,"responsibleParty":54,"collaborators":25,"id":57,"slug":25,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":25,"eligibilityCriteria":61,"healthyVolunteers":58,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":25,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":25,"overallStatus":44,"whyStopped":25,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"King Abdullah International Medical Research Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Epinephrine + Tranexamic Acid Group","EXPERIMENTAL","The experimental group will receive both epinephrine and tranexamic acid",[13],"Drug: low-dose epinephrine and tranexamic acid",{"label":15,"type":16,"description":17,"interventionNames":18},"Tranexamic Acid Group","ACTIVE_COMPARATOR","The comparator group will receive only tranexamic acid",[19],"Drug: Tranexamic Acid (TXA) treatment",[21,26],{"type":22,"name":23,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","low-dose epinephrine and tranexamic acid",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Tranexamic Acid (TXA) treatment","Tranexamic Acid",[15],[31],{"name":32,"affiliation":33,"role":34},"Wazzan Aljuhani, MD, FRCSC, MBA, MMEd","King Abdulaziz Medical City, MNGHA","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"Dr. Turki Althunayan","CONTACT","+966 55 994 4782","althunayan.tu@hotmail.com",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":25,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":25},"King Abdulaziz Medical City, Ministry of National Guard - Health Affairs","RECRUITING","Riyadh","Riyadh Region","Saudi Arabia",{"type":49,"coordinates":50},"Point",[51,52],46.72185,24.68773,{"lat":52,"lon":51},{"type":34,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Wazzan Saleh ALJuhani","Principal investigator, Orthopedic Surgeon","100599804",false,"NCT07089251","The Perioperative Outcome of Epinephrine Infusion and Tranexamic Acid in Knee Arthroplasty Surgery","Inclusion Criteria:\n\n* Patients undergoing knee joint arthroplasty.\n* Saudi and Non-Saudi Patient.\n* Patients who have Complete medical record.\n\nExclusion Criteria:\n\n* End stage renal disease\n* Liver cirrhosis\n* Coagulopathy\n* Pre-operative Hgb \\\u003C10 5.\n* History of cerebrovascular accident or myocardial infarction in past 12 months.\n* History of Heart failure.\n* History of arrhythmia.\n* History of pheochromocytoma, thyrotoxicosis and glaucoma.\n* Pregnancy or breast feeding\n* History of Deep venous thrombosis or pulmonary embolism\n* Allergy to epinephrine or tranexamic acid","ALL","18 Years","70 Years",{"count":66,"type":67},80,"ESTIMATED","INTERVENTIONAL",[70],"PHASE4","The aim of this clinical trial is to evaluate the effect of administering low-dose epinephrine and tranexamic acid on perioperative blood loss, thromboembolic complications, and hospitalization duration in patients undergoing knee joint arthroplasty.\n\nAlso aim to evaluate the effect of administering low-dose epinephrine and tranexamic acid on perioperative thromboembolic complications, and hospitalization duration",[73,74,75,76,77,78],"Knee Arthroplasty, Total","Knee Arthritis, Osteoarthritis","Total Knee Anthroplasty","Blood Loss","Tranexamic Acid Use","Epinephrine","2025-07-21",{"date":81,"type":82},"2025-07-28","ACTUAL",{"date":84,"type":82},"2025-07-15",{"date":86,"type":67},"2027-06-24",{"name":5,"class":6},1]